Health ❯ Healthcare ❯ Obesity ❯ Treatment Options

Semaglutide

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Full results will be presented at next week’s CTAD meeting after the company canceled a planned one-year extension.

Half of Semaglutide Users Quit Within a Year as Higher Dose Trials Show Bigger Losses, More Side Effects

Wegovy Wins FDA Nod for MASH as Novo Rolls Out $499 Cash Ozempic in U.S.

Novo Nordisk Launches Wegovy Weight-Loss Drug in India